ArticleCancer discovery2013
Mutant and wild-type Ras: co-conspirators in cancer.
Article in Cancer discovery, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 14 citations in OpenAlex.
- Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants.Cancer discovery · 2022Review
- An essential role for Argonaute 2 in EGFR-KRAS signaling in pancreatic cancer development.Nature communications · 2020Article
- Effect of the Up-Regulation of Circular RNA Hsa_circ_0069767 Derived from C-KIT on the Biological Behavior of Multiple Myeloma Cells.Cancer management and research · 2020Article
- Cell signaling heterogeneity is modulated by both cell-intrinsic and -extrinsic mechanisms: An integrated approach to understanding targeted therapy.PLoS biology · 2018Article
- Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration.Nature communications · 2017Article
- Quantitative Profiling of Protein Tyrosine Kinases in Human Cancer Cell Lines by Multiplexed Parallel Reaction Monitoring Assays.Molecular & cellular proteomics : MCP · 2016Article
- Towards personalized therapy in pediatric acute lymphoblastic leukemia: RAS mutations and prednisolone resistance.Haematologica · 2015Article
- Article
- Small-molecule modulation of Ras signaling.Nature chemical biology · 2014Review
- SmgGDS-558 regulates the cell cycle in pancreatic, non-small cell lung, and breast cancers.Cell cycle (Georgetown, Tex.) · 2014Article
Corrections and comments
- Comment on
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Although the functional interplay between mutant and wild-type Ras in driving tumor initiation and growth has been described, a clear picture of the precise ramifications and mechanisms of this association remains elusive, sometimes with conflicting conclusions. A report in this issue of Cancer Discovery tackles this question, which may have important implications for therapeutic strategies to block mutant Ras for cancer treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.